Arca
Skip to content

LetibotulinumtoxinA: Complete Response Letter

A complete response letter is FDA's decision not to approve an application as submitted. See BLA 761225's history or Hugel, Inc.'s company page.

On Apr 12, 2023, FDA declined to approve LetibotulinumtoxinA (BLA 761225) from Hugel, Inc in its present form, citing facility inspections, product quality, microbiology. The application was later approved.

  • Letter date: Apr 12, 2023
  • Application: BLA 761225
  • Since then: Approved

What FDA Cited

FDA's own section headings in the letter; each finds other letters citing it

Facility inspectionsProduct qualityMicrobiology

The Letter

Text from openFDA

(1) During a recent inspection of the Hugel, Inc. (FEI 3012163998) manufacturing and testing facility of drug substance and drug product for this application, our field investigator conveyed deficiencies to the representative of the facility. Satisfactory reso...… openFDA did not return the full text just now. Open it in the letter search.

Other Letters on This Application

Record

Company
Hugel, Inc
Application
BLA 761225
Status in openFDA
Approved
Review division
Center for Drug Evaluation and Research

FDA has published complete response letters since 2025, with some redactions. The status is openFDA's: whether the application was eventually approved. openFDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.